New clinical data demonstrate excellent lesion durability with PulseSelect™ Pulsed Field Ablation System in real-world setting as approvals and adoption expand globally

Rhea-AI Summary

Medtronic plc (NYSE: MDT) announced new clinical data for its PulseSelect™ Pulsed Field Ablation (PFA) System in treating atrial fibrillation (Afib). The study, presented at the Asia Pacific Heart Rhythm Society (APHRS) meeting, showed high rates of durable lesion formation:

- 98% of pulmonary veins remained isolated
- 96% of patients had all veins isolated

These results were observed approximately two months post-ablation. Dr. Devi Nair, Director of Cardiac Electrophysiology & Research at St. Bernard's Medical Center, emphasized the importance of this real-world evidence for the electrophysiology community as PFA use increases rapidly. The data adds to previous evidence establishing the safety and effectiveness of the PulseSelect technology.

Positive

• High rate of durable lesion formation: 98% of pulmonary veins remained isolated
• 96% of patients had all veins isolated two months post-ablation
• Results support previous evidence of safety and effectiveness of PulseSelect PFA System

Negative

• None.

Insights

Medical Research Analyst

The new clinical data for Medtronic's PulseSelect™ Pulsed Field Ablation (PFA) System demonstrates significant efficacy in treating atrial fibrillation. Key findings include:

• 98% durable isolation of pulmonary veins
• 96% of patients with all veins isolated
• Highly efficient procedure performed without fluoroscopy

These results are important for several reasons:

• They confirm the long-term durability of the treatment, a critical factor for patient outcomes and potential market adoption.
• The high success rate without fluoroscopy suggests improved safety and efficiency compared to traditional methods.
• The global expansion, including approvals in Japan, China and Australia, significantly broadens the potential market for Medtronic in the electrophysiology space.

For investors, this news indicates strong potential for revenue growth in Medtronic's cardiac and vascular group, particularly as the global prevalence of atrial fibrillation continues to rise. The successful launch in Japan, following reimbursement approval, is especially noteworthy given the size and aging population of that market.

Financial Analyst

This clinical data release and global expansion news for Medtronic's PulseSelect™ PFA System is positive for the company's financial outlook. Here's why:

• The strong efficacy data (98% durable isolation) could drive faster adoption rates and potentially command premium pricing.
• Expansion into key markets like Japan, China and Australia significantly increases the addressable market size.
• Reimbursement approval in Japan is crucial, as it often leads to faster revenue realization.
• The efficient, fluoroscopy-free procedure could lead to cost savings for healthcare providers, potentially accelerating adoption.

Medtronic's cardiac and vascular group, which includes electrophysiology products, generated $10.5 billion in revenue in FY2023. This new data and market expansion could help accelerate growth in this segment. While it's too early to quantify the exact impact, investors should monitor upcoming quarterly reports for signs of increased traction in electrophysiology sales, particularly in the Asia-Pacific region.

• APHRS: New data confirm robust long-term durability and highly efficient procedure performed without fluoroscopy
• Successful launch in Japan follows recent reimbursement approval  
• Approvals across APAC including China and Australia broaden reach for patients

GALWAY, Ireland and SYDNEY, Sept. 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the PulseSelect™ Pulsed Field Ablation (PFA) System in treating atrial fibrillation (Afib). Invasive remapping conducted approximately two months post-ablation with the PulseSelect PFA System demonstrated durable isolation in 98% of pulmonary veins (PV) and 96% of patients had all veins isolated.

Results were presented as a late breaking clinical trial at the Asia Pacific Heart Rhythm Society (APHRS) meeting in Sydney, Australia.

"Real-world evidence on chronic lesion formation and durability is critical as use of PFA for the treatment of Afib rapidly increases, making these results impactful and timely for the electrophysiology community," said Devi Nair, M.D., FHRS, Director of Cardiac Electrophysiology & Research, St. Bernard's Medical Center & Arrhythmia Research Group, Jonesboro, Arkansas. "Our research shows that treatment with PulseSelect results in durable lesion formation, which is the cornerstone of successful pulmonary vein isolation and an important addition to previous evidence establishing the safety and effectiveness of this technology."

About the Study
A total of 25 AFib patients with persistent or paroxysmal AFib (56% paroxysmal, 52% male, 69±9 years) undergoing pulmonary vein isolation (PVI) with the PulseSelect PFA System were evaluated. Invasive remapping conducted in all patients (57±9 days post-ablation) demonstrated durable isolation in 98% of PVs (102/104), and 96% of patients (24/25) had all veins isolated.

All index ablation procedures were conducted using intracardiac echocardiography and electroanatomical mapping (EAM) without fluoroscopy. General anesthesia was used in 24 of 25 patients, and all patients were discharged on the same day. Average skin-to-skin procedure time was 36 minutes. Acute PV isolation was achieved in 100% of patients. There were no complications during an average follow-up of 74 days.

PulseSelect Global Expansion
Broad adoption of PulseSelect continues globally, with more than 10,000 cases performed worldwide. In the Asia Pacific (APAC) region, milestones include regulatory approvals in China and Australia and launch in Japan following reimbursement approval.

Prof. Hiroshi Tada, Professor of the Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Japan, and President of the Japanese Heart Rhythm Society, said "PulseSelect is the first PFA catheter to receive reimbursement approval in Japan based on clinical trial results that include Japanese patients. We believe that the future widespread availability of this breakthrough technology under insurance coverage will be of great significance in the history of arrhythmia treatment in Japan."

"These important results clearly address the durability question and add to the real-world evidence for PulseSelect," said Rebecca Seidel, president, Cardiac Ablations Solutions business, which is part of the Cardiovascular Portfolio at Medtronic. "With expansion in new markets across the Asia Pacific region, physicians around the world are experiencing the benefits of PulseSelect, including proven safety, efficacy, efficiency and now durability as well. We are thrilled to provide this important tool to physicians for the treatment of patients with AFib."

AFib is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people worldwide.¹ Afib is a progressive disease, often beginning as paroxysmal AFib (presents intermittently) and progressing to persistent (lasts for more than 7+ days without stopping). As the disease progresses, the risk of serious complications including heart failure, stroke and risk of death increases.^2-5

For more information on PulseSelect, visit Medtronic.com.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

References

1. Roth GA, Mensah GA, Johnson CO et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol 2020;76:2982-3021.
2. Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol 2007;49:986-92.
3. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
5. Lubitz SA, Moser C, Sullivan L, et al. Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. J Am Heart Assoc 2013;2:e000126.

Contacts:
Leslie Williamson	Ryan Weispfenning
Public Relations	Investor Relations
+1-612-227-5099	+1-763-505-4626

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-clinical-data-demonstrate-excellent-lesion-durability-with-pulseselect-pulsed-field-ablation-system-in-real-world-setting-as-approvals-and-adoption-expand-globally-302261333.html

SOURCE Medtronic plc

FAQ

What are the key findings of the PulseSelect PFA System clinical study presented at APHRS 2024?

The study showed high rates of durable lesion formation, with 98% of pulmonary veins remaining isolated and 96% of patients having all veins isolated approximately two months post-ablation using the PulseSelect PFA System for treating atrial fibrillation.

How does the PulseSelect PFA System by Medtronic (MDT) perform in real-world settings?

In real-world settings, the PulseSelect PFA System demonstrated excellent lesion durability. Invasive remapping conducted about two months after the procedure showed durable isolation in 98% of pulmonary veins, indicating strong performance in treating atrial fibrillation.

What is the significance of the PulseSelect PFA System study results for Medtronic (MDT)?

The study results are significant for Medtronic as they provide real-world evidence of the PulseSelect PFA System's effectiveness, supporting its safety and efficacy. This data is important as the use of Pulsed Field Ablation for atrial fibrillation treatment rapidly increases globally.